CA2744326A1 - Tcl1 as a transcriptional regulator - Google Patents

Tcl1 as a transcriptional regulator Download PDF

Info

Publication number
CA2744326A1
CA2744326A1 CA2744326A CA2744326A CA2744326A1 CA 2744326 A1 CA2744326 A1 CA 2744326A1 CA 2744326 A CA2744326 A CA 2744326A CA 2744326 A CA2744326 A CA 2744326A CA 2744326 A1 CA2744326 A1 CA 2744326A1
Authority
CA
Canada
Prior art keywords
tcl1
cells
activator protein
tcll
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744326A
Other languages
English (en)
French (fr)
Inventor
Carlo M. Croce
Yuri Pekarsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2744326A1 publication Critical patent/CA2744326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2744326A 2008-11-21 2009-11-19 Tcl1 as a transcriptional regulator Abandoned CA2744326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (1)

Publication Number Publication Date
CA2744326A1 true CA2744326A1 (en) 2010-05-27

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744326A Abandoned CA2744326A1 (en) 2008-11-21 2009-11-19 Tcl1 as a transcriptional regulator

Country Status (7)

Country Link
US (1) US20110311555A1 (https=)
EP (1) EP2352524A1 (https=)
JP (1) JP2012509886A (https=)
CN (1) CN102271706A (https=)
AU (1) AU2009316584A1 (https=)
CA (1) CA2744326A1 (https=)
WO (1) WO2010059779A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
CA2845251A1 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
EP2487258B1 (en) 2006-01-05 2014-10-01 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
CN101535505A (zh) 2006-09-19 2009-09-16 俄亥俄州立大学研究基金会 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达
EP2087135B8 (en) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN105256004A (zh) 2007-01-31 2016-01-20 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
ES2527648T3 (es) 2007-06-08 2015-01-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de carcinoma hepatocelular
EP2719773A3 (en) 2007-06-15 2014-07-30 The Ohio State University Research Foundation miRNA as marker for acute lamphomic leucemia
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
CA2696887C (en) 2007-08-22 2016-06-28 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CN102137927B (zh) 2007-10-26 2014-03-12 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
ES2433940T3 (es) 2008-06-11 2013-12-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
AU2003224672B2 (en) * 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals

Also Published As

Publication number Publication date
JP2012509886A (ja) 2012-04-26
WO2010059779A1 (en) 2010-05-27
US20110311555A1 (en) 2011-12-22
CN102271706A (zh) 2011-12-07
AU2009316584A1 (en) 2010-05-27
EP2352524A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
US20110311555A1 (en) Tc11 as a Transcriptional Regulator
Siegel et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
Yang et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation
Weijts et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1
CA2273821C (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
Chin et al. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma
Meng et al. Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome
US20060234271A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
Weinstein et al. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors
Li et al. NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasis
Yeh et al. Isolation and properties of Gas8, a growth arrest-specific gene regulated during male gametogenesis to produce a protein associated with the sperm motility apparatus
JP2005040137A (ja) Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定
US20060094013A1 (en) Salt-inducible kinases 2 and use thereof
US7906294B2 (en) Prognosis and treatment of breast cancer
US8722637B2 (en) Methods and compositions of IG20 and DENN-SV splice variants
US20020160002A1 (en) Tumor suppressor gene
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
EP2021471B1 (en) Screening method
EP4168123B1 (en) Biomarker based patient selection for proteasome inhibitor treatment
Zhang et al. Phosphorylation dependent mitochondrial translocation of Nr4a3 provokes cardiomyocyte death
US7910704B2 (en) Human p53 splice variant displaying differential transcriptional activity
US20040009921A1 (en) Methods and compositions for the treatment of cancer
US20100113557A1 (en) Method for prevention of tumor
Ittmann Role of GGAP/PIKE-A in prostate cancer progression
Thompson Roles for protein kinase C and protein phosphatase 1 in nuclear lamina dynamics and cell cycle progression

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140807